Recurrent COVID-19 pneumonia in the course of chemotherapy: Consequence of a weakened immune system?

Abstract

One of the objectives that the scientific community is setting itself is to understand whether acquired immunity and the presence of antibodies against acute coronavirus 2 (SARS‐CoV‐2) antibodies protect against reinfection. Although there are many published papers describing how the re‐positivization of nasopharyngeal swab polymerase chain reaction real time (RT‐PCR) test and clinical healing of the subject can be justified by numerous reasons and random situations. Our aim is to highlight how there are certain populations more susceptible to re‐infection than others.